OMEROS CORP Selling, General and Administrative Expense
OMEROS CORP (OMER) reported Selling, General and Administrative Expense of $13.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-12
- OMEROS CORP selling, general and administrative expense for the quarter ending 2026-06-30 was $13.86M, a 33.97% increase year-over-year.
- OMEROS CORP selling, general and administrative expense for the quarter ending 2026-03-31 was $13.37M, a 20.19% increase year-over-year.
- OMEROS CORP selling, general and administrative expense for the quarter ending 2025-12-31 was $9.63M, a 3.99% decline year-over-year.
- OMEROS CORP selling, general and administrative expense for the quarter ending 2025-09-30 was $10.40M, a 8.18% decline year-over-year.
- OMEROS CORP selling, general and administrative expense for fiscal 2025 was $41.50M, a 12.50% decline from fiscal 2024.
- OMEROS CORP selling, general and administrative expense for fiscal 2024 was $47.43M, a 4.49% decline from fiscal 2023.
- OMEROS CORP selling, general and administrative expense for fiscal 2023 was $49.66M, a 1.99% decline from fiscal 2022.
- OMEROS CORP selling, general and administrative expense for fiscal 2022 was $50.67M, a 7.61% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $13.86M 10-Q · filed 2026-08-12 | $27.23M 10-Q · filed 2026-08-12 | $36.86M derived: sum of 3 quarters · filed 2026-08-12 | $47.26M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $13.37M 10-Q · filed 2026-05-13 | $23.00M derived: sum of 2 quarters · filed 2026-05-13 | $33.40M derived: sum of 3 quarters · filed 2026-05-13 | $43.75M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $20.03M derived: sum of 2 quarters · filed 2026-03-31 | $30.38M derived: sum of 3 quarters · filed 2026-08-12 | $41.50M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $10.40M 10-Q · filed 2025-11-13 | $20.74M derived: sum of 2 quarters · filed 2026-08-12 | $31.86M 10-Q · filed 2025-11-13 | $41.90M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $10.35M 10-Q · filed 2026-08-12 | $21.47M 10-Q · filed 2026-08-12 | $31.50M derived: sum of 3 quarters · filed 2026-08-12 | $42.83M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $11.12M 10-Q · filed 2026-05-13 | $21.16M derived: sum of 2 quarters · filed 2026-05-13 | $32.48M derived: sum of 3 quarters · filed 2026-05-13 | $46.29M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $21.36M derived: sum of 2 quarters · filed 2026-03-31 | $35.17M derived: sum of 3 quarters · filed 2026-03-31 | $47.43M 10-K · filed 2026-03-31 | $49.73M 10-K · filed 2025-03-31 |
| 2024-09-30 | $11.32M 10-Q · filed 2025-11-13 | $25.13M derived: sum of 2 quarters · filed 2025-11-13 | $37.40M 10-Q · filed 2025-11-13 | $48.27M derived: sum of 4 quarters · filed 2026-03-31 | |
| 2024-06-30 | $13.81M 10-Q · filed 2025-08-14 | $26.07M 10-Q · filed 2025-08-14 | $36.95M derived: sum of 3 quarters · filed 2026-03-31 | $53.37M derived: sum of 4 quarters · filed 2026-03-31 | |
| 2024-03-31 | $12.26M 10-Q · filed 2025-05-15 | $23.14M derived: sum of 2 quarters · filed 2026-03-31 | $39.56M derived: sum of 3 quarters · filed 2026-03-31 | $50.82M derived: sum of 4 quarters · filed 2026-03-31 | |
| 2023-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $27.30M derived: sum of 2 quarters · filed 2026-03-31 | $38.56M derived: sum of 3 quarters · filed 2026-03-31 | $49.66M 10-K · filed 2026-03-31 | |
| 2023-09-30 | $16.42M 10-Q · filed 2024-11-13 | $27.68M derived: sum of 2 quarters · filed 2024-11-13 | $38.78M 10-Q · filed 2024-11-13 | $52.37M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-06-30 | $11.26M 10-Q · filed 2024-08-07 | $22.36M 10-Q · filed 2024-08-07 | $35.95M derived: sum of 3 quarters · filed 2025-03-31 | $48.15M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-03-31 | $11.10M 10-Q · filed 2024-05-15 | $24.69M derived: sum of 2 quarters · filed 2025-03-31 | $36.89M derived: sum of 3 quarters · filed 2025-03-31 | ||
| 2022-12-31 | $13.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $25.79M derived: sum of 2 quarters · filed 2025-03-31 | $50.67M 10-K · filed 2025-03-31 | ||
| 2022-09-30 | $12.20M 10-Q · filed 2023-11-09 | $37.08M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $54.84M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |